27
Thu, Apr
22 New Articles

We offer a complete range of services, from cell line and strain development through process development and large-scale manufacturing to fill and finish. Our extensive portfolio of capabilities and technologies includes the production of antibodies, recombinant proteins, non-antibody scaffolds, Fab fragments as well as pDNA from either mammalian cell culture or microbial fermentation systems.

Galena Biopharma, a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, announced it has acquired Mills Pharmaceuticals, which has the worldwide rights to GALE-401 (Anagrelide CR), a patented, controlled release formulation of anagrelide.

More Articles ...

Sign up via our free email subscription service to receive notifications when new information is available.
captcha